Highlights

  • 1

    Goals of neoadjuvant therapy; pCR as an endpoint in TNBC

  • 2

    How to improve pCR in TNBC

  • 3

    Optimizing taxanes in TNBC

  • 4

    DNA damaging agents

  • 5

    Immunotherapy

  • 6

    Is there a role for adjuvant therapy in TNBC in 2020?

  • 7

    Take home messages

Summary

Summarizing “Neoadjuvant vs adjuvant approaches in early TNBC” ESMO presentation is discussed.

Interviewee

User

Javier Cortes, MD PhD

Head, Breast Cancer Program IOB Institute of ...

Madrid, Spain

Author of more than 140 publications, especially about breast tumours and new drugs, and more than 300 communications at different conferences.

User

Antoine Abugaber

Niagara Falls, Ontario

While in the Medical Department in large Pharma he held the positions of; Director of Clinical Operations, International Clinical Research and Develop...

Comments (0)